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Abstract
Background
Since the use of pneumococcal conjugate vaccines PCV7 and PCV13 in children became
widespread, invasive pneumococcal disease (IPD) has dramatically decreased. Neverthe-
less, there has been a rise in incidence of Streptococcus pneumoniae non-vaccine sero-
types (NVT) colonising the human nasopharynx. Nasopharyngeal colonisation, an
essential step in the development of S. pneumoniae-induced IPD, is associated with biofilm
formation. Although the capsule is the main pneumococcal virulence factor, the formation of
pneumococcal biofilms might, in fact, be limited by the presence of capsular polysaccharide
(CPS).
Methodology/Principal Findings
We used clinical isolates of 16 emerging, non-PCV13 serotypes as well as isogenic trans-
formants of the same serotypes. The biofilm formation capacity of isogenic transformants
expressing CPSs from NVT was evaluated in vitro to ascertain whether this trait can be
used to predict the emergence of NVT. Fourteen out of 16 NVT analysed were not good bio-
film formers, presumably because of the presence of CPS. In contrast, serotypes 11A and
35B formed45% of the biofilm produced by the non-encapsulated M11 strain.
Conclusions/Significance
This study suggest that emerging, NVT serotypes 11A and 35B deserve a close surveillance.
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Introduction
Streptococcus pneumoniae (pneumococcus) is a leading human pathogen that naturally inhab-
its the upper respiratory tract. It usually colonises the associated mucosal surfaces in early
childhood, and persists as a symptomless commensal (carrier state) in the nasopharynx [1].
Carriage is higher in children less than 5 years and decreases with age and is generally higher in
developing countries and among economically deprived populations. Once carriage is estab-
lished, however, S. pneumoniaemay invade several sterile sites, leading to what is known as in-
vasive pneumococcal disease (IPD). Indeed, the pneumococcus is responsible for episodes of
bacteraemic community-acquired pneumonia, bacteraemia and meningitis, mainly in children,
the elderly, and immunocompromised patients [2]. In addition, pneumococci are the main
ethiologic agent of non-bacteraemic community-acquired pneumonia and a major cause of
other non-invasive diseases such as acute otitis media, sinusitis, and conjunctivitis.
The pneumococcal capsule is composed of polysaccharides (capsular polysaccharide or
CPS) that, in most cases, are covalently bound to the cell wall. At least 95 different pneumococ-
cal serotypes are currently known, each with a biochemically different CPS. The capsule is the
main pneumococcal virulence factor since it allows the bacterium to evade the host immune
system by blocking phagocytosis [2]. Pneumococcal vaccines [3] are based on combinations of
CPSs, and include a) a 23-valent pneumococcal polysaccharide vaccine; b) a 7-valent conjugate
vaccine (PCV7), directed at serotypes 4, 6B, 9V, 14, 18C, 19F and 23F, but no longer available
in the market; c) a 10-valent conjugate vaccine (PCV10), licensed in Europe (but not in the
United States) and directed at serotypes 1, 5, and 7F in addition to the serotypes included in
PCV7; and d) a 13-valent pneumococcal conjugate vaccine (PCV13) that was licensed five
years ago; this subsequently replaced PCV7. PCV13 includes six conjugate CPSs of serotypes 1,
3, 5, 6A, 7F, and 19A in addition to the serotypes included in PCV7.
The widespread use of conjugate vaccines has been very effective in reducing cases of IPD,
although increases in disease caused by non-vaccine serotypes (NVT) (“serotype replacement”)
have subsequently offset some of these reductions. Although the PCV7 serotype 6B appears to
offer cross-protection against the non-PCV7 serotype 6A, this is not the case for 19F and the
non-PCV7 serotype 19A [4]. Indeed, the incidence of infections caused by 19A multiresistant
pneumococcus has increased since PCV7 vaccination became common. NVT are also on the
rise in the current post-PCV7/PCV13 era. Surveillance program results suggest that pneumo-
cocci of various serogroups/serotypes not included in PCV13 (e.g., 11, 12, 15, 22F, 23A, 23B,
33F, 24, 34, and 35B) are rapidly increasing in prevalence worldwide [5–8]. Serotype 6C pneu-
mococci, which are good biofilm formers [9] and whose CPS is not included in PCV13, were
not investigated further.
Concerns about serotype replacement have influenced recent policy discussions [10]. Pre-
dicting the amount of future replacement is difficult since the reasons underlying a particular
NVT increases after vaccine introduction are not fully understood. In the years immediately
preceding PCV13 introduction, no single non-PCV13 serotype seemed an obvious candidate
for replacement, based on current rates of disease, antimicrobial resistance, and carriage data.
We recently proposed that quantifying the in vitro biofilm formation capacity of isogenic S.
pneumoniae transformants expressing different CPSs might help predict the emergence (and
eventual expansion) of NVT that are prone to colonise the human nasopharynx [9]. In that
work we showed that clinical isolates and isogenic pneumococcal transformants of serotypes
19F and 19A (but not those of serotypes 19B and 19C) are capable of forming substantial
amounts of biofilm in vitro. Strains of serogroup 6 also showed significant biofilm-forming
capacity.
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In the present study, 16 isogenic pneumococcal transformants expressing CPSs of non-
PCV13 serotypes were constructed to determine whether biofilm formation can reliably predict
the emergence of NVT of S. pneumoniae that colonise the human nasopharynx.
Materials and Methods
Media, growth conditions, DNA purification, and genetic transformation
Table 1 shows the pneumococcal strains examined. Clinical isolates of S. pneumoniae were
from the collection of the Spanish Pneumococcal Reference Laboratory (SPRL; Centro Nacio-
nal de Microbiología ISCIII, Majadahonda, Madrid, Spain). All strains were grown in liquid
CpH8 medium supplemented (or not) with 0.08% yeast extract (C+Y medium), or in solid me-
dium involving trypticase soy agar or D agar supplemented with 5% defibrinated sheep blood
(Thermo Scientific; Hampshire, England) [11]. Growth was controlled by measuring the opti-
cal density at 550 nm (OD550).
S. pneumoniae chromosomal DNA was purified from clinical strains and encapsulated, iso-
genic transformants constructed by transformation of strain M11, as described elsewhere [9].
The selection of transformants was made by enriching those encapsulated by successive trans-
fer to C+A medium (CpH8 containing 0.08% of bovine seroalbumin) supplemented with
0.5 μl/ml anti-R antiserum (which agglutinates only non-encapsulated pneumococci) [9]. Sero-
typing of S. pneumoniae was kindly performed by D. Vicioso at the SPRL.
Biofilm formation assay, quantification, and statistical analysis
The optimal conditions for biofilm formation by pneumococcal cells on polystyrene microtitre
plates have been previously described [11,14]. In short, pneumococcal cells were grown in C+Y
medium at 37°C to an OD550 of 0.5–0.6 and diluted (1:100) in fresh C+Ymedium. Aliquots
(200 μl) were dispensed into each well in triplicate, and the plate incubated at 34°C for 6 h. Growth
(OD595) was measured and the biofilm formed was stained with 1% crystal violet [11]. In the pres-
ent study, a strain was considered as “good” or “intermediate” biofilm producer when it formed
45% or between 10% and 30% of the biofilm formed by the control, non-encapsulated M11
strain respectively. The data for biofilm formation include the mean ± standard error of at least
three independent experiments, each performed in triplicate. Statistical significance was examined
using the Student t test. For multiples comparisons, one-way analyses of variance (ANOVA) were
performed, followed by Tukey’s post hoc test when the ANOVA rejected the null hypothesis. The
SAS 9.3 statistical packge (SAS Institute, Cary, NC) was used for all analyses. Differences were con-
sidered statistically significant when P<0.05.
Results
Fig 1 shows the biofilm formation capacity of clinical isolates of S. pneumoniae belonging to 16
non-PCV13 serotypes (Table 1). Two clinical isolates of each serotype were analysed in detail.
Although pneumococci of every serotype tested produced less biofilm than the non-encapsu-
lated strain M11, significant differences were noted in the biofilm formation capacity of several
pairs of clinical strains of the same serotype: e.g., strains 2901 and 2963 (serotype 11A), 2948
and 2990 (serotype 15B/C), and 1544 and 3004 (serotype 23A). This confirms previous obser-
vations indicating that the genetic background, and not only the CPS, modulates pneumococ-
cal attachment to the artificial substrate [9,11,15].
Since in vitro biofilm formation by pneumococcus depends on many different genes and/or
biochemical traits, the use of isogenic transformants (i.e., strains differing only by a single trait)
is necessary when the influence of CPS in biofilm formation is to be measured. To this end, the
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Table 1. Strains of S. pneumoniae used in this studya.
Strain Description/serotype (source) Reference/Sourceb
M11 Non-encapsulated strain derived from R6 (Hex–, lytA+) [9]
2977/13 8 (blood) SPRL
3013/13 8 (blood) SPRL
6028/95 8 (blood) [12]
P012 M11 transformant with DNA from strain 6028/95; serotype 8 D. Llull, CIB
2965/13 9N (bronchial aspirate) SPRL
3015/13 9N (blood) SPRL
P238 M11 transformant with DNA from strain 3015/13; serotype 9N This study
2960/13 10A (blood) SPRL
3011/13 10A (blood) SPRL
P245 M11 transformant with DNA from strain 3011/13; serotype 10A This study
2901/13 11A (sputum) SPRL
2963/13 11A (blood) SPRL
P242 M11 transformant with DNA from strain 2963/13; serotype 11A This study
2951/13 12F (blood) SPRL
2995/13 12F (blood) SPRL
SSISP12F/1 12F (not determined) Staten Seruminstitut
P020 M11 transformant with DNA from strain SSISP12F/1; serotype 12F D. Llull, CIB
2949/13 15A (blood) SPRL
2957/13 15A (blood) SPRL
P247 M11 transformant with DNA from strain 2949/13; serotype 15A This study
2948/13c 15B/C (bronchial aspirate) SPRL
2990/13c 15B/C (otic exudate) SPRL
SSISP15B/1 15B (sputum) Staten Seruminstitut
P013 M11 transformant with DNA from strain SSISP15B/1; serotype 15B D. Llull, CIB
1572/14 16F (blood) SPRL
1607/14 16F (blood) SPRL
P246 M11 transformant with DNA from strain 1572/14; serotype 16F This study
3014/13 22F (blood) SPRL
3022/13 22F (blood) SPRL
P244 M11 transformant with DNA from strain 3014/13; serotype 22F This study
1544/14 23A (cerebrospinal ﬂuid) SPRL
3004/13 23A (blood) SPRL
P240 M11 transformant with DNA from strain 3004/13; serotype 23A This study
2971/13 23B (sputum) SPRL
3000/13 23B (aqueous humor) SPRL
P248 M11 transformant with DNA from strain 3000/13; serotype 23B This study
2966/13 24F (blood) SPRL
3017/13 24F (blood) SPRL
P224 M11 transformant with DNA from strain 3017/13; serotype 24F [9]
436/96 31 (not determined) SPRL
2847/13 31 (sputum) SPRL
2959/13 31 (blood) SPRL
P016 M11 transformant with DNA from strain 436/96; serotype 31 D. Llull, CIB
2975/13 33F (blood) SPRL
2922/13 33F (blood) SPRL
SSISP33F/1 33F (not determined) Staten Seruminstitut
(Continued)
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non-encapsulated M11 strain was transformed with DNA prepared from the corresponding
clinical isolates, and at least two independent transformants of each serotype were analysed.
Since initial experiments revealed no significant differences between them, only one trans-
formed strain of each serotype was studied further. The serotype 35B strains were the best bio-
film producers; the P241 transformant strain produced 50% of the biofilm formed by M11.
In addition, the P242 transformant (serotype 11A) was capable of synthesizing up to 45% of
the biofilm produced by its non-encapsulated progenitor. Intermediate biofilm formation was
noted for the isogenic S. pneumoniae transformants of serotype 23A. In contrast, serotype 33F
pneumococci (whether clinical isolates or M11 transformant) were unable to produce any sub-
stantial quantity of biofilm in vitro (Fig 1).
Some variation was noted in the growth rate and/or biofilm formation capacity of the differ-
ent strains (Fig 1). Consequently, the biofilm formation values for the encapsulated strains
were normalised for the OD of the culture measured as stated in Materials and Methods, and
the presented percentages were calculated in relation to the parental strain M11 [11]. Fig 2
shows the relative biofilm formation capacity of the isogenic transformants of the non-PCV13
serotypes compared with that of M11. Every serotype analysed formed significantly less biofilm
than the non-encapsulated strain, although serotypes 35B and 11A formed significantly more
biofilm than the other serotypes analysed.
Discussion
Recent years have seen continuous interest in the impact of pneumococcal conjugate vaccines
on nasopharyngeal colonisation [16]. In fact, surveillance of colonisation has become an im-
portant component of the vaccination monitoring process in the post-licensure setting. Naso-
pharyngeal colonisation, which is associated with biofilm formation, is an essential step in the
development of S. pneumoniae disease and prevention of colonisation may reduce host-to-host
transmission [17,18]. Moreover, colonisation by multiple serotypes (co-colonisation), which
Table 1. (Continued)
Strain Description/serotype (source) Reference/Sourceb
P017 M11 transformant with DNA from strain SSISP33F/1; serotype 33F D. Llull, CIB
2967/13 35F (sputum) SPRL
3012/13 35F (blood) SPRL
P239 M11 transformant with DNA from strain 2967/13; serotype 35F This study
2896/13 35B (blood) SPRL
2943/13 35B (conjunctivitis) SPRL
P241 M11 transformant with DNA from strain 2943/13; serotype 35B This study
aStrains are ordered by serotype.
bSPRL, Spanish Pneumococcal Reference Laboratory (Centro Nacional de Microbiología ISCIII,
Majadahonda, Madrid, Spain).
cWhether these strains are of serotype 15B or 15C could not be determined. While some studies consider
15B and 15C to be separate entities, their coding regions differ by only a single TA tandem repeat in the
wciZ gene, which results in a single difference in the O-acetyl structure. The CPS of serotype 15B is the O-
acetylated variant of that possessed by 15C CPS [13]. Although upon ﬁrst isolation from a patient
serotypes 15B and 15C can be accurately differentiated, after few in vitro passages, this is not usually
possible since these serotypes can interconvert. Therefore, serotypes 15B and 15C were considered
together in the present study.
doi:10.1371/journal.pone.0125636.t001
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appears to be much more prevalent than previously envisaged [19], is an important factor to
consider as it facilitates horizontal gene transfer [20]. Thus, the ability of pneumococcal sero-
types to form biofilms—which a previous publication [9] and the present study show can be
rapidly tested in vitro—could be used to help predict the expansion of NVT. This method has
recently shown isogenic transformants and clinical isolates of serotype 19A and serogroup 6,
which were emerging during the PCV7 era, to be good biofilm-formers [9], and many studies
have shown that the non-PCV13 serotypes analysed in the present study underwent a rapid in-
crease in prevalence after PCV13 implementation. Nevertheless, no previous studies have as-
sessed the ability of these serotypes to form biofilms in vitro.
The present results clearly show that most (14 out of 16) of the clinical isolates or isogenic
transformants expressing the CPSs of NVT were unable to form substantial amounts of biofilm
in vitro. Although an inverse relationship between CPS and biofilm formation exists [14], it has
previously been shown that a minimum amount of CPS is necessary for efficient nasopharyn-
geal colonisation in mice [15]. The situation, however, is far from clear. For example, S. pneu-
moniae isolates of serotypes 8, 22F and 33F, which were found both in carriage and causing
IPD, and which are potentially highly invasive [21], failed to produce substantial amounts of
biofilms in vitro in the present study. This finding strongly suggests that in vitro biofilm forma-
tion is mostly unrelated to IPD-inducing capacity. It should be underlined that the CPSs of se-
rotypes 22F and 33F are included in a 15-valent pneumococcal conjugate vaccine that is
currently under pre-clinical evaluation [22].
Fig 1. Biofilm formation.Growth and biofilm formation by S. pneumoniae clinical isolates of the indicated serotypes, and their encapsulated M11
transformants. In all cases, open bars indicate bacterial growth. Hatched and blackened bars indicate, respectively, biofilm formation by either clinical
isolates or their encapsulated M11 transformants. Grey bars correspond to biofilm formation by the M11 strain. Biofilm formation by the M11 strain was
determined in all experiments with mean values between serotypes that were not significantly different (P >0.05 using one-way ANOVA).
doi:10.1371/journal.pone.0125636.g001
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The present results also show that the biofilm formation capacity of the corresponding iso-
genic transformants almost paralleled (and in some cases exceeded) that of the corresponding
clinical isolates. One exception was seen, however: the clinical isolate 2948 (serotype 15B/C)
(Fig 1). This strain showed significantly more biofilm formation capacity than strain P013, an
M11 transformant of serotype 15B obtained using DNA from the reference strain SSISP15B/1
(Table 1). It may be that strain 2948 has a genetic background more prone to allow biofilm for-
mation than strains M11 and 2990. It should be reminded that the serotypes of strains 2948
and 2990 were not determined; they might not, therefore, belong to the same serotype (Table 1,
see footnote c).
In sharp contrast to the other serotypes tested here, isogenic transformants expressing the
CPS of serotype 35B or 11A were capable of producing substantial amounts of biofilm in vitro,
forming45% of the amount of biofilm produced by the non-encapsulated M11 strain (Fig 2).
This may explain the current prevalence of these serotypes in the human nasopharynx [23,24].
Many factors appear to influence the colonisation capacity of pneumococcal serotypes. For
example, a previous study showed CPS (the major determinant of surface charge in S. pneumo-
niae) to be associated with colonisation capacity [25]. With the notable exceptions of serotypes
19A and 11A, higher net negative surface charge was associated with higher resistance to non-
opsonic, neutrophil-mediated killing as well as higher carriage prevalence. It has also been sug-
gested that a direct relationship exists between the success (in terms of relative numbers) of a
serotype during carriage and the biochemistry of its CPS [26]. In fact, it has been recently
shown that the CPSs of clinical isolates and isogenic transformants expressing the CPS of sero-
types 19F and 19A, and all members of serogroup 6 (which are good biofilm producers), all in-
clude the disaccharides α-D-Glcp-(1!2)-α-L-Rhap-(1! and α-D-Glcp-(1!3)-α-L-Rhap-
(1! [9]. However, neither of these disaccharides is present in the capsules of serotypes 11A or
Fig 2. Relative biofilm formation.Relative biofilm formation capacity of M11 isogenic transformants with
non-PCV13 serotypes compared to that of their parental non-encapsulated strain (M11). The percentages
shown are the mean ± standard error of at least three independent experiments, each performed in triplicate.
Relative biofilm formation was significantly different between serotypes (*, P <0.0001 in a one-way ANOVA).
The Tukey’s post hoc test showed significant differences in biofilm formation between serotypes 35B and
11A, and the rest of serotypes. No significant differences were observed between the biofilm-forming
capacity of serotypes 35B and 11A.
doi:10.1371/journal.pone.0125636.g002
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35B (Fig 3). In addition, no chemical similarities between serotypes 11A and 35B CPSs are ob-
vious—although both contain O-acetylated galactose residues. Recently, Calix et al. [27]
showed that the newly discovered, invasive serotype 11E contains loss-of-function mutations
in the capsule O-acetyltransferase gene wcjE, and does not express β-D-Galp6Ac at all. It is re-
markably that, although frequently found in carriers, serotype 11A shows low invasiveness due
to ficolin-2 recognition of O-acetylated capsule epitopes and the consequent activation of the
lectin complement pathway activation [28]. It it well known that some serotypes are rarely
found in carriage although they are known to cause disease, e.g., serotypes/serogroups 1, 3, 5,
and 7 [29], but the reasons underlying how and when pneumococcal colonisation will result in
dissemination and disease remain poorly understood [16,30–32].
There is increasing interest in the interactions between the different species of the nasopha-
ryngeal microbiota, because of the possibility that PCV vaccination might affect the ecology of
the nasopharynx, which could have clinical consequences. This topic is subjected to debate; for
example, an inverse relation between carriage of pneumococcus and Staphylococcus aureus has
been found in some studies [33,34], but not in others [35–37].
Evaluating vaccine efficacy for protection against colonisation with S. pneumoniae and
other bacterial pathogens is an area of growing interest [38]. Conjugate vaccines lead to a re-
duction in the carriage prevalence of vaccine-serotype pneumococci in both vaccinated and un-
vaccinated individuals and a reduction in hospital admissions for invasive and non-invasive
pneumococcal pneumonia in children younger than 5 years, as well as in some adult age
groups, indicating herd protection [39]. Interestingly, it has been shown that estimating the
adult burden of pneumococcal disease from bacteraemic pneumococcal pneumonia data alone
significantly underestimates the true burden of disease in adults. For every case of bacteraemic
pneumococcal pneumonia, it has been estimated that there are at least 3 additional cases of
non-bacteraemic pneumococcal pneumonia [40]. Management of these infections is potential-
ly being compromised by the increasing resistance of the pathogen to antibiotics commonly
used to treat these infections [41]. Of note, increasing antibiotic resistance has been recently
detected both in serotype 35B [42,43] and serotype 11A S. pneumoniae isolates [44]. However,
since pneumococcal vaccines have been dessigned for the active prevention of IPD and pneu-
mococci of serotypes 11A and 35B only seldom cause IPD [45–47], it is questionable whether
these serotypes should be included in future higher-valency PCVs. Yet, further studies of sur-
veillance are needed in order to detect the emergence of non PCV-13 serotypes and allow ratio-
nal vaccine design, implementation and continued effective control of pneumococcal disease.
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Fig 3. Primary structures of the capsular polysaccharides of S. pneumoniae serotypes 11A and 35B.
Data were taken from previous studies [13,27].
doi:10.1371/journal.pone.0125636.g003
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